Search

Your search keyword '"Ayello, Janet"' showing total 566 results
Start Over Author "Ayello, Janet"
566 results on '"Ayello, Janet"'

1. Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning “Two Keys” simultaneously

Author

Luo, Wen, Hoang, Hai, Miller, Katherine E., Zhu, Hongwen, Xu, Serena, Mo, Xiaokui, Garfinkle, Elizabeth A. R., Costello, Heather, Wijeratne, Saranga, Chemnitz, Wiebke, Gandhi, Ronan, Liao, Yanling, Ayello, Janet, Gardenswartz, Aliza, Rosenblum, Jeremy M., Cassady, Kevin A., Mardis, Elaine R., Lee, Dean A., Cripe, Timothy P., and Cairo, Mitchell S.

Published
2024
Full Text
View/download PDF

3. Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease

Author

Chu, Yaya, Talano, Julie-An, Baxter-Lowe, Lee Ann, Verbsky, James W, Morris, Erin, Mahanti, Harshini, Ayello, Janet, Keever-Taylor, Carolyn, Johnson, Bryon, Weinberg, Rona S, Shi, Qiuhu, Moore, Theodore B, Fabricatore, Sandra, Grossman, Brenda, van de Ven, Carmella, Shenoy, Shalini, and Cairo, Mitchell S

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Hematology, Sickle Cell Disease, Transplantation, Stem Cell Research - Nonembryonic - Human, Rare Diseases, Stem Cell Research, Organ Transplantation, Clinical Trials and Supportive Activities, Clinical Research, Pediatric, Inflammatory and immune system, Good Health and Well Being, Child, Humans, Transplantation, Haploidentical, Hematopoietic Stem Cell Transplantation, Leukocytes, Mononuclear, Chimerism, Immune Reconstitution, Anemia, Sickle Cell, Cytokines, sickle cell disease, donor chimerism, immune reconstitution, HLA antibodies, CD34 enrichment, donor grafts, NK, haploidentical transplantation, Medical Microbiology, Biochemistry and cell biology, Genetics
Abstract

IntroductionWe previously reported the initial results of a phase II multicenter transplant trial using haploidentical parental donors for children and aolescents with high-risk sickle cell disease achieving excellent survival with exceptionally low rates of graft-versus-host disease and resolution of sickle cell disease symptoms. To investigate human leukocyte antigen (HLA) sensitization, graft characteristics, donor chimerism, and immune reconstitution in these recipients.MethodsCD34 cells were enriched using the CliniMACS® system with a target dose of 10 x 106 CD34+ cells/kg with a peripheral blood mononuclear cell (PBMNC) addback dose of 2x105 CD3/kg in the final product. Pre-transplant HLA antibodies were characterized. Donor chimerism was monitored 1-24 months post-transplant. Comprehensive assessment of immune reconstitution included lymphocyte subsets, plasma cytokines, complement levels, anti-viral T-cell responses, activation markers, and cytokine production. Infections were monitored.ResultsHLA antibodies were detected in 7 of 11 (64%) evaluable patients but rarely were against donor antigens. Myeloid engraftment was rapid (100%) at a median of 9 days. At 30 days, donor chimerism was 93-99% and natural killer cell levels were restored. By 60 days, CD19 B cells were normal. CD8 and CD4 T-cells levels were normal by 279 and 365 days, respectively. Activated CD4 and CD8 T-cells were elevated at 100-365 days post-transplant while naïve cells remained below baseline. Tregs were elevated at 100-270 days post-transplant, returning to baseline levels at one year. At one year, C3 and C4 levels were above baseline and CH50 levels were near baseline. At one year, cytokine levels were not significantly different from baseline.DiscussionThese results suggest that haploidentical transplantation with CD34-enriched cells and peripheral blood mononuclear cell addback results in rapid engraftment, sustained donor chimerism and broad-based immune reconstitution.

Published
2022

4. Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation.

Author

Friedman, Deborah, Dozor, Allen J, Milner, Jordan, D'Souza, Marise, Talano, Julie-An, Moore, Theodore B, Shenoy, Shalini, Shi, Qiuhu, Walters, Mark C, Vichinsky, Elliott, Parsons, Susan K, Braniecki, Suzanne, Moorthy, Chitti R, Ayello, Janet, Flower, Allyson, Morris, Erin, Mahanti, Harshini, Fabricatore, Sandra, Klejmont, Liana, van de Ven, Carmella, Baxter-Lowe, Lee Ann, and Cairo, Mitchell S

Subjects
Lung, Humans, Anemia, Sickle Cell, Vital Capacity, Hematopoietic Stem Cell Transplantation, Prospective Studies, Child, Sickle Cell Disease, Clinical Research, Transplantation, Rare Diseases, Pediatric, Stem Cell Research, Hematology, Clinical Trials and Supportive Activities, Respiratory, Clinical Sciences, Oncology and Carcinogenesis, Immunology
Abstract

Children with sickle cell disease (SCD) are at high-risk of progressive, chronic pulmonary and cardiac dysfunction. In this prospective multicenter Phase II trial of myeloimmunoablative conditioning followed by haploidentical stem cell transplantation in children with high-risk SCD, 19 patients, 2.0-21.0 years of age, were enrolled with one or more of the following: history of (1) overt stroke; (2) silent stroke; (3) elevated transcranial Doppler velocity; (4) multiple vaso-occlusive crises; and/or (5) two or more acute chest syndromes and received haploidentical transplants from 18 parental donors. Cardiac and pulmonary centralized cores were established. Pulmonary function results were expressed as percent of the median of healthy reference cohorts, matched for age, sex, height and race. At 2 years, pulmonary functions including forced expiratory volume (FEV), FEV1/ forced vital capacity (FVC), total lung capacity (TLC), diffusing capacity of lung for carbon monoxide (DLCO) were stable to improved compared to baseline values. Importantly, specific airway conductance was significantly improved at 2 years (p

Published
2021

5. Efficiently targeting neuroblastoma (NB) by the combination of anti-ROR1 CAR NK cells and N-803 in-vitro and in-vivo of NB xenografts

Author

Chu, Yaya, primary, Nayyar, Gaurav, additional, Tian, Meijuan, additional, Lee, Dean A., additional, Ozkaynak, Mehmet F., additional, Ayala-Cuesta, Jessica, additional, Klose, Kayleigh, additional, Foley, Keira, additional, Mendelowitz, Alyssa S., additional, Luo, Wen, additional, Liao, Yanling, additional, Ayello, Janet, additional, Behbehani, Gregory K., additional, Riddell, Stanley, additional, Cripe, Tim, additional, and Cairo, Mitchell S., additional

Published
2024
Full Text
View/download PDF

6. Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model

Author

Chu, Yaya, Lee, Sanghoon, Shah, Tishi, Yin, Changhong, Barth, Matthew, Miles, Rodney R, Ayello, Janet, Morris, Erin, Harrison, Lauren, Van de Ven, Carmella, Galardy, Paul, Goldman, Stanton C, Lim, Megan S, Hermiston, Michelle, McAllister-Lucas, Linda M, Giulino-Roth, Lisa, Perkins, Sherrie L, and Cairo, Mitchell S

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Orphan Drug, Lymphoma, Cancer, Rare Diseases, Clinical Research, Pediatric, Ibrutinib, Bruton's Tyrosine Kinase, Burkitt Lymphoma, Xenografted NSG Mice, Cell Proliferation, Bruton’s Tyrosine Kinase, Immunology, Oncology and carcinogenesis
Abstract

Pediatric and adult patients with recurrent/refractory Burkitt lymphoma (BL) continue to have poor outcomes, emphasizing the need for newer therapeutic agents. Bruton's tyrosine kinase (BTK) is activated following B-cell receptor stimulation and in part regulates normal B-cell development. Ibrutinib, a selective and irreversible BTK inhibitor, has been efficacious in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, and marginal zone lymphoma. In this study, we investigated the efficacy of ibrutinib alone and in selective adjuvant combinations against BL in-vitro and in a human BL xenografted immune-deficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mouse model. Our data demonstrated that phospho-BTK level was significantly reduced in BL cells treated with ibrutinib (p

Published
2019

7. Adenoviral Cellular Therapy with Adenovirus (ADV)-Specific Cytotoxic T-Lymphocytes (CTLs) for Resistant Infections in Children, Adolescent, and Young Adult (CAYA) Patients Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT): A Promising Approach

Author

Schaefer, Edo, primary, Vu, Christine, additional, Flower, Allyson, additional, Ayello, Janet, additional, Chu, Yaya, additional, van de Ven, Carmella, additional, Mintzer, Elizabeth, additional, Harrison, Lauren, additional, Morris, Erin, additional, Wang, Yongping, additional, Shenoy, Shalini, additional, Lee, Dean Anthony, additional, Abu-Arja, Rolla, additional, Johnson, Bryon D, additional, Verneris, Michael R., additional, Dvorak, Christopher C., additional, Chu, Julia, additional, Cooke, Kenneth R., additional, Talano, Julie A, additional, Bunin, Nancy J., additional, and Cairo, Mitchell S., additional

Published
2024
Full Text
View/download PDF

12. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma.

Author

Wen Luo, Hai Hoang, Yanling Liao, Jian Pan, Ayello, Janet, and Cairo, Mitchel S.

Subjects
EWING'S sarcoma, LABORATORY mice, ANIMAL models in research, ANIMAL disease models, KILLER cells
Abstract

The advent of novel cancer immunotherapy approaches is revolutionizing the treatment for cancer. Current small animal models for most cancers are syngeneic or genetically engineered mouse models or xenograft models based on immunodeficient mouse strains. These models have been limited in evaluating immunotherapy regimens due to the lack of functional human immune system. Development of animal models for bone cancer faces another challenge in the accessibility of tumor engraftment sites. Here, we describe a protocol to develop an orthotopic humanized mouse model for a bone and soft tissue sarcoma, Ewing sarcoma, by transplanting fresh human cord blood CD34+ hematopoietic stem cells into young NSG-SGM3 mice combined with subsequent Ewing sarcoma patient derived cell engraftment in the tibia of the humanized mice. We demonstrated early and robust reconstitution of human CD45+ leukocytes including T cells, B cells, natural killer cells and monocytes. Ewing sarcoma xenograft tumors successfully orthotopically engrafted in the humanized mice with minimal invasive procedures. We validated the translational utility of this orthotopic humanized model by evaluating the safety and efficacy of an immunotherapy antibody, magrolimab. Treatment with magrolimab induces CD47 blockade resulting in significantly decreased primary tumor growth, decreased lung metastasis and prolonged animal survival in the established humanized model. Furthermore, the humanized model recapitulated the dose dependent toxicity associated with the CD47 blockade as observed in patients in clinical trials. In conclusion, this orthotopic humanized mouse model of Ewing sarcoma represents an improved platform for evaluating immunotherapy in bone and soft tissue sarcoma, such as Ewing sarcoma. With careful design and optimization, this model is generalizable for other bone malignancies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with High-Risk Sickle Cell Disease (SCD) or Beta Thalassemia Major Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)

Author

Schaefer, Edo, primary, Milner, Jordan, additional, Hung, Justine, additional, Ayello, Janet, additional, Shi, Qiuhu, additional, Talano, Julie, additional, Moore, Theodore B., additional, Friedman, Deborah, additional, Dozor, Allen J, additional, Klejmont, Liana, additional, Mahanti, Harshini, additional, Morris, Erin, additional, Fabricatore, Ms. Sandra, additional, Mintzer, Elizabeth, additional, Guillerman, R. Paul, additional, Flower, Allyson, additional, Cooke, Kenneth R., additional, and Cairo, Mitchell S., additional

Published
2023
Full Text
View/download PDF

15. Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-γ Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

Author

Flower, Allyson, primary, Talano, Julie, additional, Ayello, Janet, additional, Rigot, Olivia, additional, Harrison, Lauren, additional, Morris, Erin, additional, Mintzer, Elizabeth, additional, Maryamchick, Elena, additional, Wang, Yongping, additional, O’Donnell, Lynn C., additional, Abu-Arja, Rolla, additional, Lee, Dean A., additional, Johnson, Bryon D, additional, Chu, Julia, additional, Dvorak, Christopher C., additional, Shenoy, Shalini, additional, Bunin, Nancy J., additional, and Cairo, Mitchell S., additional

Published
2023
Full Text
View/download PDF

16. Anti-IL1RAP Chimeric Antigen Receptor Modified Ex-Vivo Expanded TGF-Beta Imprinted Natural Killer Cells Against Ewing Sarcoma

Author

Luo, Wen, primary, Zhang, Hai-Feng, additional, Hoang, Hai, additional, Chu, Yaya, additional, Ayello, Janet, additional, Li, Wei, additional, Scopim-Ribeiro, Renata, additional, Lizardo, Michael M, additional, Rouleau, Melanie, additional, Dimitrov, Dimiter S, additional, Lee, Dean Anthony, additional, Sorensen, Poul H, additional, and Cairo, Mitch S., additional

Published
2023
Full Text
View/download PDF

17. Manufacture, Immunological Characterization and Clinical Response of GMP Grade Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs® Cytokine Capture System

Author

Chu, Yaya, primary, Lamb, Margaret, additional, Maryamchik, Elena, additional, Rigot, Olivia, additional, Ayello, Janet, additional, Harrison, Lauren, additional, Mintzer, Elizabeth, additional, Shaw, Rosemarie, additional, Behbehani, Gregory, additional, Mardis, Elaine, additional, Miller, Katherine, additional, Rao Venkata, Lakshmi Prakruthi, additional, Chang, Hsiaochi, additional, Lee, Dean A., additional, Rosenthal, Elana Y., additional, Kadauke, Stephan, additional, Bunin, Nancy J., additional, Talano, Julie, additional, Johnson, Bryon D, additional, Wang, Yongping, additional, and Cairo, Mitchell S., additional

Published
2023
Full Text
View/download PDF

18. Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes

Author

Chu, Yaya, primary, Milner, Jordan, additional, Lamb, Margaret, additional, Maryamchik, Elena, additional, Rigot, Olivia, additional, Ayello, Janet, additional, Harrison, Lauren, additional, Shaw, Rosemarie, additional, Behbehani, Gregory K, additional, Mardis, Elaine R, additional, Miller, Katherine, additional, Prakruthi Rao Venkata, Lakshmi, additional, Chang, Hsiaochi, additional, Lee, Dean, additional, Rosenthal, Elana, additional, Kadauke, Stephan, additional, Bunin, Nancy, additional, Talano, Julie-An, additional, Johnson, Bryon, additional, Wang, Yongping, additional, and Cairo, Mitchell S, additional

Published
2022
Full Text
View/download PDF

19. Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease

Author

Chu, Yaya, primary, Talano, Julie-An, additional, Baxter-Lowe, Lee Ann, additional, Verbsky, James W., additional, Morris, Erin, additional, Mahanti, Harshini, additional, Ayello, Janet, additional, Keever-Taylor, Carolyn, additional, Johnson, Bryon, additional, Weinberg, Rona S., additional, Shi, Qiuhu, additional, Moore, Theodore B., additional, Fabricatore, Sandra, additional, Grossman, Brenda, additional, van de Ven, Carmella, additional, Shenoy, Shalini, additional, and Cairo, Mitchell S., additional

Published
2022
Full Text
View/download PDF

22. 303 Targeting Ewing sarcoma with anti-IL1RAP chimeric antigen receptor modified natural killer cells

Author

Luo, Wen, primary, Sorensen, Poul, additional, Cairo, Mitchell, additional, Hoang, Hai, additional, Chu, Yaya, additional, Ayello, Janet, additional, Li, Wei, additional, Lizardo, Michael, additional, Ribeiro, Renata, additional, Rouleau, Melanie, additional, Dimitrov, Dimiter, additional, Lee, Dean, additional, and Zhang, Hai-Feng, additional

Published
2022
Full Text
View/download PDF

23. Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma

Author

Gardenswartz, Aliza, primary, Mehta, Brinda, additional, El-Mallawany, Nader Kim, additional, van de Ven, Carmella, additional, Hochberg, Jessica, additional, Flower, Allyson, additional, Morris, Erin, additional, Harrison, Lauren, additional, Chu, Yaya, additional, Basso, Jaclyn, additional, Gerard, Perry, additional, Islam, Humayun, additional, Ayello, Janet, additional, Baxter-Lowe, Lee Ann, additional, and Cairo, Mitchell S., additional

Published
2022
Full Text
View/download PDF

26. Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes.

Author

Chu, Yaya, Milner, Jordan, Lamb, Margaret, Maryamchik, Elena, Rigot, Olivia, Ayello, Janet, Harrison, Lauren, Shaw, Rosemarie, Behbehani, Gregory K, Mardis, Elaine R, Miller, Katherine, Venkata, Lakshmi Prakruthi Rao, Chang, Hsiaochi, Lee, Dean, Rosenthal, Elana, Kadauke, Stephan, Bunin, Nancy, Talano, Julie-An, Johnson, Bryon, and Wang, Yongping

Subjects
CYTOTOXIC T cells, SARS-CoV-2, MONONUCLEAR leukocytes, TUMOR necrosis factors, COVID-19
Abstract

Background Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 virus-specific cytotoxic T-cell lymphocytes (vCTLs) could provide a promising modality in COVID-19 treatment. We aimed to screen, manufacture, and characterize SARS-CoV-2–vCTLs generated from convalescent COVID-19 donors using the CliniMACS Cytokine Capture System (CCS). Methods Donor screening was done by stimulation of convalescent COVID-19 donor peripheral blood mononuclear cells with viral peptides and identification of interferonγ (IFN-γ)+ CD4 and CD8 T cells using flow cytometry. Clinical-grade SARS-CoV-2–vCTLs were manufactured using the CliniMACS CCS. The enriched SARS-CoV-2–vCTLs were characterized by T-cell receptor sequencing, mass cytometry, and transcriptome analysis. Results Of the convalescent donor blood samples, 93% passed the screening criteria for clinical manufacture. Three validation runs resulted in enriched T cells that were 79% (standard error of the mean 21%) IFN-γ+ T cells. SARS-CoV-2–vCTLs displayed a highly diverse T-cell receptor repertoire with enhancement of both memory CD8 and CD4 T cells, especially in CD8 TEM, CD4 TCM, and CD4 TEMRA cell subsets. SARS-CoV-2–vCTLs were polyfunctional with increased gene expression in T-cell function, interleukin, pathogen defense, and tumor necrosis factor superfamily pathways. Conclusions Highly functional SARS-CoV-2–vCTLs can be rapidly generated by direct cytokine enrichment (12 hours) from convalescent donors. Clinical Trials Registration NCT04896606. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma

Author

Gardenswartz, Aliza, Mehta, Brinda, El-Mallawany, Nader Kim, van de Ven, Carmella, Hochberg, Jessica, Flower, Allyson, Morris, Erin, Harrison, Lauren, Chu, Yaya, Basso, Jaclyn, Gerard, Perry, Islam, Humayun, Ayello, Janet, Baxter-Lowe, Lee Ann, and Cairo, Mitchell S.

Subjects
STEM cell transplantation, YOUNG adults, NON-Hodgkin's lymphoma, CORD blood transplantation, TEENAGERS
Abstract

To the Editor: More than half of the non-Hodgkin lymphomas (NHL) occurring in children, adolescents, and young adults (CAYA) in North America and Europe are comprised mature B-cell NHL (B-NHL) [[1]]. Salvage reinduction regimens resulted in 6/12 (50%) patients achieving a CR, 5/12 (41.6%) patients attaining a PR and 1/12 (8.3%) patients with progressive disease (PD). Post MAC autoSCT 7/12 patients (58%) were in a CR, two patients (16.7%) were in a PR, two patients (16.7%) had stable disease and one patient (8.3%) had PD. Amongst the three patients with diffuse large B-cell lymphoma one was in CR, one had stable disease and one had PD post MAC autoSCT. [Extracted from the article]

Published
2023
Full Text
View/download PDF

28. 320 - Safety and Efficacy of High Dose Granulocyte Colony Stimulating Factor Mobilization in Familial Haploidentical Adult Donors with Sickle Cell Trait Followed By CD34+ Cell Enrichment and Mononuclear Cell Add-Back Prior to Haploidentical Allogeneic Transplantation in High-Risk Sickle Cell Disease Recipients

Author

Milner, Jordan, Flower, Allyson, Schulman, Stephanie, Keever-Taylor, Carolyn A, Fabricatore, Sandra, Morris, Erin, Mahanti, Harshini, Shi, Qiuhu, Shaw, Rosemarie, Weinberg, Rona Singer, Grossman, Brenda, Talano, Julie-An, Shenoy, Shalini, Moore, Theodore B., Ayello, Janet, van de Ven, Carmella, and Cairo, Mitch S.

Published
2022
Full Text
View/download PDF

29. Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti-Mcam Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells

Author

Luo, Wen, primary, Gardenswartz, Aliza, additional, Chu, Yaya, additional, Rosenblum, Jeremy, additional, Ayello, Janet, additional, Marcondes, Mario Q., additional, Overwijk, Willem W, additional, Cripe, Timothy P, additional, Cassady, Kevin A, additional, Lee, Dean Anthony, additional, and Cairo, Mitch S., additional

Published
2022
Full Text
View/download PDF

30. Feasibility, Safety and Efficacy of Haploidentical Viral Cytotoxic T-Lymphocytes for Children, Adolescents, and Young Adults (CAYA) with Refractory Viral Infections in Primary Immunodeficiencies (PID) Post Solid Organ Transplant (SOT) or Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT)

Author

Milner, Jordan, primary, Talano, Julie-An, additional, Harrison, Lauren, additional, Ayello, Janet, additional, Flower, Allyson, additional, Chu, Yaya, additional, Rigot, Olivia, additional, Johnson, Bryon D, additional, Li, Yimei, additional, Lee, Dean Anthony, additional, Abu-Arja, Rolla, additional, Chu, Julia, additional, Dvorak, Christopher C., additional, O’Donnell, Lynn C., additional, Wang, Yongping, additional, Bunin, Nancy J., additional, and Cairo, Mitch S., additional

Published
2022
Full Text
View/download PDF

31. Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with High-Risk Sickle Cell Disease (SCD) or Beta Thalassemia Major Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)

Author

Schaefer, Edo, primary, Milner, Jordan, additional, Hung, Justine, additional, Ayello, Janet, additional, Shi, Qiuhu, additional, Talano, Julie-An, additional, Moore, Theodore B., additional, Friedman, Deborah, additional, Dozor, Allen J, additional, Klejmont, Liana, additional, Mahanti, Harshini, additional, Morris, Erin, additional, Fabricatore, Sandra, additional, Mintzer, Elizabeth, additional, Flower, Allyson, additional, Cooke, Kenneth R., additional, and Cairo, Mitch S., additional

Published
2022
Full Text
View/download PDF

32. Safety and Efficacy of High Dose Granulocyte Colony Stimulating Factor Mobilization in Familial Haploidentical Adult Donors with Sickle Cell Trait Followed By CD34+ Cell Enrichment and Mononuclear Cell Add-Back Prior to Haploidentical Allogeneic Transplantation in High-Risk Sickle Cell Disease Recipients

Author

Milner, Jordan, primary, Flower, Allyson, additional, Schulman, Stephanie, additional, Keever-Taylor, Carolyn A, additional, Fabricatore, Sandra, additional, Morris, Erin, additional, Mahanti, Harshini, additional, Shi, Qiuhu, additional, Shaw, Rosemarie, additional, Weinberg, Rona Singer, additional, Grossman, Brenda, additional, Talano, Julie-An, additional, Shenoy, Shalini, additional, Moore, Theodore B., additional, Ayello, Janet, additional, van de Ven, Carmella, additional, and Cairo, Mitch S., additional

Published
2022
Full Text
View/download PDF

36. Manufacture and Immunological Characterization of GMP-Compliant Functional Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs ® Cytokine Capture System

Author

Chu, Yaya, primary, Milner, Jordan, additional, Lamb, Margaret, additional, Maryamchik, Elena, additional, Rigot, Olivia, additional, Ayello, Janet, additional, Harrison, Lauren, additional, Shaw, Rosemarie, additional, Behbehani, Greg K., additional, Mardis, Elaine R., additional, Miller, Katherine E, additional, Venkata, Lakshmi Prakruthi Rao, additional, Chang, Hsiaochi, additional, Lee, Dean Anthony, additional, Rosenthal, Elana Y., additional, Kadauke, Stephan, additional, Bunin, Nancy, additional, Talano, Julie-An, additional, Johnson, Bryon, additional, Wang, Yongping, additional, and Cairo, Mitchell S., additional

Published
2021
Full Text
View/download PDF

37. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre-B-ALL

Author

Awasthi, Aradhana, Ayello, Janet, Van de Ven, Carmella, Elmacken, Mona, Sabulski, Anthony, Barth, Matthew J., Czuczman, Myron S., Islam, Humayun, Klein, Christian, and Cairo, Mitchell S.

Published
2015
Full Text
View/download PDF

38. An Age-Dependent Pharmacokinetic Study of Intravenous and Oral Mycophenolate Mofetil in Combination with Tacrolimus for GVHD Prophylaxis in Pediatric Allogeneic Stem Cell Transplantation Recipients

Author

Bhatia, Monica, Militano, Olga, Jin, Zhezhen, Figurski, Michal, Shaw, Leslie, Moore, Virginia, Morris, Erin, Tallamy, Bradford, van deVen, Carmella, Ayello, Janet, Baxter-Lowe, LeeAnn, Satwani, Prakash, George, Diane, Bradley, M. Brigid, Garvin, James, and Cairo, Mitchell S.

Published
2010
Full Text
View/download PDF

39. Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

Author

Flower, Allyson M., Friedmann, Rachel, Ayello, Janet, Rigot, Olivia, Harrison, Lauren, Morris, Erin, Sturhahn, Meghan, Maryamchik, Elana, Wang, Yongping, O'Donnell, Lynn, Abu-Arja, Rolla, Lee, Dean Anthony, Talano, Julie-An, Johnson, Bryon, Bunin, Nancy, and Cairo, Mitchell S

Published
2020
Full Text
View/download PDF

40. Optimization of Gating of IFN-Gamma Positive Viral Specific Cytotoxic T-Cells (vCTLs) Following Viral Peptivators® Stimulation Utilizing the Cytokine Capture System on the Clinimacs® Prodigy: Quality Control of the Viral CTL Consortium (VIRCTL)

Author

Rigot, Olivia, primary, Ayello, Janet, additional, Fallon, Bernadette, additional, Colon, Lin Marie, additional, Kuhns, Robert, additional, Harrison, Lauren, additional, Shaw, Rosemarie, additional, Fabricatore, Sandra, additional, Gonzalez, Isabel D, additional, Flower, Allyson, additional, Johnson, Bryon D, additional, Wang, Yongping, additional, and Cairo, Mitchell S., additional

Published
2021
Full Text
View/download PDF

41. Safety and Efficacy of GMP Clinical Grade Manufacturing of Virus Specific Cytotoxic T Lymphocytes (vCTLS) Against Cytomegalovirus (CMV), Epstein Barr Virus ( EBV), Adenovirus (ADV) and BKV to Treat Medically Refractory Viral Infections Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Children, Adolescents and Young Adults (CAYA) (IND# 17449)

Author

Ayello, Janet, primary, Flower, Allyson, additional, Kuhns, Robert, additional, Colon, Lin Marie, additional, Fallon, Bernadette, additional, Rigot, Olivia, additional, Shaw, Rosemarie, additional, Harrison, Lauren, additional, Morris, Erin, additional, Sturhahn, Meghan, additional, Gonzalez, Isabel D, additional, Wang, Yongping, additional, O’Donnell, Lynn C., additional, Lee, Dean Anthony, additional, Talano, Julie-An, additional, Johnson, Bryon D, additional, Bunin, Nancy J., additional, and Cairo, Mitchell S., additional

Published
2021
Full Text
View/download PDF

42. Stable to Improved Long Term Cardiac and Pulmonary Function in Children, Adolescents, and Young Adults with High Risk Sickle Cell Disease Following Myeloimmunoablative Conditioning and Familial Haploidentical Stem Cell Transplantation

Author

Milner, Jordan, primary, Friedman, Deborah, additional, Dozor, Allen J, additional, D’Souza, Marise D, additional, Talano, Julie-An, additional, Moore, Theodore B, additional, Shenoy, Shalini, additional, Shi, Qiuhu, additional, Keever-Taylor, Carolyn A, additional, Weinberg, Rona S, additional, Grossman, Brenda, additional, Walters, Mark C., additional, Vichinsky, Elliot P., additional, Parsons, Susan K., additional, Braniecki, Suzanne, additional, McKinstry, Robert, additional, Verbsky, James, additional, Moorthy, Chitti R, additional, Ayello, Janet, additional, Flower, Allyson, additional, Chu, Yaya, additional, Morris, Erin, additional, Mahanti, Harshini, additional, Fabricatore, Sandra, additional, Militano, Olga, additional, Klejmont, Liana, additional, van de Ven, Carmella, additional, Baxter-Lowe, Lee Ann, additional, and Cairo, Mitchell S., additional

Published
2021
Full Text
View/download PDF

43. Rapid Engraftment, Immune Cell Reconstitution and Sustained Donor Chimerism in Patients Receiving G-CSF Mobilized Peripheral Blood Stem Cells (PB-SC) from Related or Unrelated Donors Undergoing CD34 Enrichment with Mononuclear Cell (T cell) Addback in Children, Adolescents, and Adults with Malignant and Nonmalignant Diseases

Author

Milner, Jordan, primary, Nichols, Cydney, additional, Ayello, Janet, additional, Seiter, Karen P., additional, Liu, Delong, additional, Morris, Erin, additional, Fabricatore, Sandra, additional, Chu, Yaya, additional, Shaw, Rosemarie, additional, van de Ven, Carmella, additional, Flower, Allyson M., additional, and Cairo, Mitchell S, additional

Published
2020
Full Text
View/download PDF

44. Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Author

Chu, Yaya, primary, Talano, Julie-An, additional, Baxter-Lowe, Lee Ann, additional, Keever-Taylor, Carolyn A., additional, Morris, Erin, additional, Mahanti, Harshini, additional, Ayello, Janet, additional, Johnson, Bryon, additional, Weinberg, Rona Singer, additional, Shi, Qiuhu, additional, Moore, Theodore B., additional, Fabricatore, Sandra, additional, Grossman, Brenda J., additional, van de Ven, Carmella, additional, Shenoy, Shalini, additional, and Cairo, Mitchell S, additional

Published
2020
Full Text
View/download PDF

45. 423 - Manufacture, Immunological Characterization and Clinical Response of GMP Grade Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs® Cytokine Capture System

Author

Chu, Yaya, Lamb, Margaret, Maryamchik, Elena, Rigot, Olivia, Ayello, Janet, Harrison, Lauren, Mintzer, Elizabeth, Shaw, Rosemarie, Behbehani, Gregory, Mardis, Elaine, Miller, Katherine, Rao Venkata, Lakshmi Prakruthi, Chang, Hsiaochi, Lee, Dean A., Rosenthal, Elana Y., Kadauke, Stephan, Bunin, Nancy J., Talano, Julie, Johnson, Bryon D, Wang, Yongping, and Cairo, Mitchell S.

Published
2023
Full Text
View/download PDF

46. 424 - Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-γ Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

Author

Flower, Allyson, Talano, Julie, Ayello, Janet, Rigot, Olivia, Harrison, Lauren, Morris, Erin, Mintzer, Elizabeth, Maryamchick, Elena, Wang, Yongping, O’Donnell, Lynn C., Abu-Arja, Rolla, Lee, Dean A., Johnson, Bryon D, Chu, Julia, Dvorak, Christopher C., Shenoy, Shalini, Bunin, Nancy J., and Cairo, Mitchell S.

Published
2023
Full Text
View/download PDF

48. 394 - Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with High-Risk Sickle Cell Disease (SCD) or Beta Thalassemia Major Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)

Author

Schaefer, Edo, Milner, Jordan, Hung, Justine, Ayello, Janet, Shi, Qiuhu, Talano, Julie, Moore, Theodore B., Friedman, Deborah, Dozor, Allen J, Klejmont, Liana, Mahanti, Harshini, Morris, Erin, Fabricatore, Ms. Sandra, Mintzer, Elizabeth, Guillerman, R. Paul, Flower, Allyson, Cooke, Kenneth R., and Cairo, Mitchell S.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results